Showing 6261-6270 of 8699 results for "".
- Pinnacle Dermatology Acquires SkinSpeaks Dermatology Clinics in Twin Citieshttps://practicaldermatology.com/news/pinnacle-dermatology-acquires-skinspeaks-dermatology-clinics-in-twin-cities/2460205/Pinnacle Dermatology has acquired SkinSpeaks in the Twin Cities area including locations in Edina, Woodbury, Burnsville, Blaine and Crystal. “We welcome the patients and staff of SkinSpeaks to the Pinnacle Dermatology network of prac
- AbbVie Launches “Let Me Be Clear” to Urge Psoriasis Patients to Speak Uphttps://practicaldermatology.com/news/abbvie-launches-let-me-be-clear-to-urge-psoriasis-patients-to-speak-up/2460202/AbbVie is launching Let Me Be
- Cynosure Enters the Muscle Toning Market in Europe, Middle Easthttps://practicaldermatology.com/news/cynosure-enters-the-muscle-toning-market-in-europe-middle-east/2460200/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Going for the Gold: Sebacia Microparticles Help Direct Lasers to the Source of Acnehttps://practicaldermatology.com/news/going-for-the-gold-sebacia-microparticles-help-direct-lasers-to-the-source-of-acne/2460199/Sebacia microparticles may be acne’s latest and greatest nemesis. New research presented the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago shows that the technology helps to safely and effectively clear acne wh
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints,
- FDA Approves Amzeeq Minocycline Foam from Foamixhttps://practicaldermatology.com/news/fda-approves-amzeeq-minocycline-foam-from-foamix/2460194/The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Amzeeq, formerly known as FMX101, is the first topical minoc
- Consumers Cite Dermatologists as Top Influencers of Cosmetic Procedure, Skin Care Choices: ASDShttps://practicaldermatology.com/news/consumers-site-dermatologists-as-top-influencers-of-cosmetic-procedure-skin-care-choices-asds/2460191/When it comes to consumer decisions on cosmetic procedures and skin care choices, dermatologists are the leading influencers, results of the 2019
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderat
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum c